The results of the "component-target" network analysis showed that the efficacy of THSWD in the treatment of breast cancer is not only focused on promoting tumor cell apoptosis and inhibiting tumor proliferation (PIK3CA, PIK3R1, MAPK3, AKT1, JUN, STAT3) core targets, it also focuses on improving the tumor microenvironment, inhibiting angiogenesis (HIF, VEGFA), and immune regulation (IL6, IL1B, IL10) and other related targets. Here, JUN is linked to neoplasm.